Ariel Weinberger | Chief Executive Officer
Autonomous Therapeutics

Ariel Weinberger, Chief Executive Officer, Autonomous Therapeutics

Dr. Ariel Weinberger is the CEO & Founder of Autonomous Therapeutics. Ari started Autonomous from a single bench in the Brooklyn Navy Yard in 2017, and grew the company to a team of more than 20 at Johnson & Johnson’s JLABS incubator in New York City. At JLABS, Autonomous was selected as one of the first companies for J&J’s Blue Knight collaboration with BARDA. Ari and the team have raised substantial funding from the U.S. Government and venture capital—and have developed a new class of RNA (Encrypted RNA™) that enables precision and resistance-proof therapeutics from COVID-19 to Hepatitis B. Ari completed his Ph.D. in Biophysics at the University of California, Berkeley, where he was a DoD NDSEG fellow and received the California HIV/AIDS Dissertation Prize. He completed his postdoctoral training as an NIH Ruth L. Kirschstein Fellow at Harvard. Prior to founding Autonomous, Ari was a Principal Investigator and Wyss Institute Technology Development Fellow at Harvard Medical School.


Day 1 - November 28 @ 14:20

Encrypted RNA: A new class of RNA for inhalable & variant-proof immunity

Day 3 - November 30 @ 09:40

Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

  • Could new platform technologies enable us to develop countermeasures rapidly enough to stop emerging viral threats before pandemics ensue?
  • Are broad-spectrum (pan-variant) prophylactics a possible way forward?
  • When will we see the first clinically approved mRNA or DNA-encoded therapeutics, from gene-editing to immunotherapy?
  • Could advances in AI and synthetic biology enable personalized medicines (e.g. for cancers) to be developed at a population scale?
  • Would regulators agree to accelerate approval of platform-based medicines based on the safety and efficacy of different candidates from the same platform?
  • Can Government, biopharma, and venture capital co-fund platform technologies, especially for technologies of dual commercial and national security interest?
last published: 02/Jan/24 12:15 GMT

back to speakers